PER Postgame™: Protecting Patients with MS from COVID-19—Exploring the Latest in Prevention and Immunosuppressive Treatment Strategies
January 5, 2022
January 5, 2023
If you are seeking ACPE credit as a Pharmacist, please click this link: www.pharmacytimes.org/per-postgame. For all others, please click the start activity button to continue.
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Genentech, Inc.
- Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)™
- Nurses — 1.25 Contact Hours
- Pharmacists — 1.25 Contact Hours
All other health care professionals completing this course will be issued a statement of participation.
This educational activity is directed toward community neurologists, neuroimmunologists, MS specialists, specialty nurse practitioners, physician assistants, registered nurses, pharmacists, and other members of the MS care team.
The COVID-19 pandemic is an unprecedented health care crisis with disproportionate impact on immunocompromised populations. There are unanswered questions and a lack of understanding about the immune response to SARS-CoV-2 vaccines in patients with multiple sclerosis (MS) treated with disease modifying therapies (DMTs). With a continually changing therapeutic landscape based on emerging evidence, clinicians managing patients with MS require timely education on balancing SARS-CoV-2 infection risk with optimal disease control. This program sheds more light on cell-mediated responses to vaccines, how SARS-CoV-2 vaccines work, and current evidence surrounding DMTs for MS and vaccine response.
The PER Postgame™ is an innovative and unique webcast by PER®. It is an in-depth, engaging data recap program, focusing on novel therapeutic agents and emerging treatment strategies discussed at major medical meetings. This program focuses on abstracts presented at the 2021 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.
Upon successful completion of this activity, you should be better prepared to:
- Describe the immunological pathways activated by vaccine administration
- Explain the mechanisms underlying the antiviral efficacy of current SARSCoV-2 vaccines
- Discuss the impact of disease-modifying therapies (DMTs) on anti-SARS-CoV-2 vaccine response in patients with MS
- Implement timely, evidence-based strategies for addressing COVID-19 in patients with MS
Matthew A. Tremblay, MD, PhD
Director of Multiple Sclerosis Research
Multiple Sclerosis Comprehensive Care Center
Department of Medicine
RWJ Barnabas Health
Livingston, New Jersey
Aimee M. Banks, PharmD, BCPS, MSCS
Clinical Pharmacist, Multiple Sclerosis
Vanderbilt University Medical Center
Joseph J. Sabatino, Jr., MD, PhD
Assistant Adjunct Professor Department of Neurology
University of California San Francisco
San Francisco, California
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC, and Pharmacy Times Continuing Education™.
Physician Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.
Pharmacy Accreditation Statement
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This activity is approved for 1.25 contact hours (0.125 CEU) under the ACPE universal activity number 0290-0000-21-431-H01-P. The activity is available for CE credit through December 23, 2022.
This CE activity is also offered free online at www.pharmacytimes.org/per-postgame where you will be directed to the activity in its entirety, including the online pretest and posttest, activity evaluation, and request for credit.
Disclosures of Conflicts of Interest
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
- Matthew A. Tremblay, MD, PhD
- Grant research support: Biogen.
- Consultant: Genentech.
- Speaker’s Bureau: Genentech.
- Aimee M. Banks, PharmD, BCPS, MSCS
- Advisory Board Consultant: Bristol Myers Squibb, EMD Serono, TG Therapeutics.
- Joseph J. Sabatino, Jr., MD, PhD
- Grant research support: Novartis Pharmaceuticals.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.